193 related articles for article (PubMed ID: 26489961)
21. Pharmacokinetic and pharmacodynamic modeling of the effect of an sodium-glucose cotransporter inhibitor, phlorizin, on renal glucose transport in rats.
Yamaguchi K; Kato M; Suzuki M; Asanuma K; Aso Y; Ikeda S; Ishigai M
Drug Metab Dispos; 2011 Oct; 39(10):1801-7. PubMed ID: 21712434
[TBL] [Abstract][Full Text] [Related]
22. A simple and rapid LC-MS/MS method for quantitation of luseogliflozin in rat plasma and its application to a PK study.
Kobuchi S; Matsuno M; Kawamoto M; Kojima N; Ito Y; Yamashita M; Sakaeda T
Bioanalysis; 2017 Jan; 9(2):163-171. PubMed ID: 27960548
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of NS-105, a novel cognition enhancer. 1st communication: absorption, metabolism and excretion in rats, dogs and monkeys after single administration of 14C-NS-105.
Mukai H; Sugimoto T; Ago M; Morino A
Arzneimittelforschung; 1999 Nov; 49(11):881-90. PubMed ID: 10604039
[TBL] [Abstract][Full Text] [Related]
24. Failure to confirm a sodium-glucose cotransporter 2 inhibitor-induced hematopoietic effect in non-diabetic rats with renal anemia.
Yamazaki D; Konishi Y; Morikawa T; Kobara H; Masaki T; Hitomi H; Osafune K; Nakano D; Kittikulsuth W; Nishiyama A
J Diabetes Investig; 2020 Jul; 11(4):834-843. PubMed ID: 31880858
[TBL] [Abstract][Full Text] [Related]
25. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria.
Chino Y; Samukawa Y; Sakai S; Nakai Y; Yamaguchi J; Nakanishi T; Tamai I
Biopharm Drug Dispos; 2014 Oct; 35(7):391-404. PubMed ID: 25044127
[TBL] [Abstract][Full Text] [Related]
26. Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans.
Kumar GN; Jayanti VK; Johnson MK; Uchic J; Thomas S; Lee RD; Grabowski BA; Sham HL; Kempf DJ; Denissen JF; Marsh KC; Sun E; Roberts SA
Pharm Res; 2004 Sep; 21(9):1622-30. PubMed ID: 15497688
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of metabolism and disposition of GDC-0152 in rats using 14C labeling strategy at two different positions: a novel formation of hippuric acid from 4-phenyl-5-amino-1,2,3-thiadiazole.
Yue Q; Mulder T; Rudewicz PJ; Solon E; Budha N; Ware JA; Lyssikatos J; Hop CE; Wong H; Khojasteh SC
Drug Metab Dispos; 2013 Feb; 41(2):508-17. PubMed ID: 23223496
[TBL] [Abstract][Full Text] [Related]
28. Metabolism and disposition of [14C]BMS-690514 after oral administration to rats, rabbits, and dogs.
Hong H; Su H; Sun H; Allentoff A; Ekhato IV; Chando T; Caceres-Cortes J; Roongta V; Iyer RA; Humphreys WG; Christopher LJ
Drug Metab Dispos; 2010 Jul; 38(7):1189-201. PubMed ID: 20363952
[TBL] [Abstract][Full Text] [Related]
29. Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys.
Maeshiba Y; Kiyota Y; Yamashita K; Yoshimura Y; Motohashi M; Tanayama S
Arzneimittelforschung; 1997 Jan; 47(1):29-35. PubMed ID: 9037440
[TBL] [Abstract][Full Text] [Related]
30. Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man.
Mizojiri K; Okabe H; Sugeno K; Misaki A; Ito M; Kominami G; Esumi Y; Takaichi M; Harada T; Seki H; Inaba A
Arzneimittelforschung; 1997 Mar; 47(3):259-69. PubMed ID: 9105544
[TBL] [Abstract][Full Text] [Related]
31. Luseogliflozin, a sodium-glucose cotransporter-2 inhibitor, reverses cerebrovascular dysfunction and cognitive impairments in 18-mo-old diabetic animals.
Wang S; Jiao F; Border JJ; Fang X; Crumpler RF; Liu Y; Zhang H; Jefferson J; Guo Y; Elliott PS; Thomas KN; Strong LB; Urvina AH; Zheng B; Rijal A; Smith SV; Yu H; Roman RJ; Fan F
Am J Physiol Heart Circ Physiol; 2022 Feb; 322(2):H246-H259. PubMed ID: 34951541
[TBL] [Abstract][Full Text] [Related]
32. Disposition and metabolism of a novel diurea inhibitor of acyl CoA: cholesterol acyltransferase (YM17E) in the rat and dog.
Uchida T; Nakamura E; Usui T; Imasaki H; Kawakami R; Watanabe T; Higuchi S
Xenobiotica; 1994 Dec; 24(12):1223-36. PubMed ID: 7771109
[TBL] [Abstract][Full Text] [Related]
33. Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling.
Zhang D; Wang L; Raghavan N; Zhang H; Li W; Cheng PT; Yao M; Zhang L; Zhu M; Bonacorsi S; Yeola S; Mitroka J; Hariharan N; Hosagrahara V; Chandrasena G; Shyu WC; Humphreys WG
Drug Metab Dispos; 2007 Jan; 35(1):150-67. PubMed ID: 17062777
[TBL] [Abstract][Full Text] [Related]
34. Discovery of potent, low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor SGL5213 for type 2 diabetes treatment.
Kuroda S; Kobashi Y; Oi T; Kawabe K; Shiozawa F; Okumura-Kitajima L; Sugisaki-Kitano M; Io F; Yamamoto K; Kakinuma H
Bioorg Med Chem; 2019 Jan; 27(2):394-409. PubMed ID: 30579799
[TBL] [Abstract][Full Text] [Related]
35. Metabolism and disposition in rats, dogs, and humans of erdafitinib, an orally administered potent pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor.
Scheers E; Borgmans C; Keung C; Bohets H; Wynant I; Poggesi I; Cuyckens F; Leclercq L; Mamidi RNVS
Xenobiotica; 2021 Feb; 51(2):177-193. PubMed ID: 32902324
[TBL] [Abstract][Full Text] [Related]
36. Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human.
Waters NJ; Smith SA; Olhava EJ; Duncan KW; Burton RD; O'Neill J; Rodrigue ME; Pollock RM; Moyer MP; Chesworth R
Cancer Chemother Pharmacol; 2016 Jan; 77(1):43-62. PubMed ID: 26645404
[TBL] [Abstract][Full Text] [Related]
37. Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans.
Denissen JF; Grabowski BA; Johnson MK; Buko AM; Kempf DJ; Thomas SB; Surber BW
Drug Metab Dispos; 1997 Apr; 25(4):489-501. PubMed ID: 9107549
[TBL] [Abstract][Full Text] [Related]
38. Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro.
Gerisch M; Heinig R; Engelen A; Lang D; Kolkhof P; Radtke M; Platzek J; Lovis K; Rohde G; Schwarz T
Drug Metab Dispos; 2018 Nov; 46(11):1546-1555. PubMed ID: 30171161
[TBL] [Abstract][Full Text] [Related]
39. Preclinical metabolism and the disposition of vornorexant/TS-142, a novel dual orexin 1/2 receptor antagonist for the treatment of insomnia.
Konno Y; Kamigaso S; Toki H; Terasaka S; Hikichi H; Endo H; Yamaguchi JI; Mizuno-Yasuhira A
Pharmacol Res Perspect; 2024 Apr; 12(2):e1183. PubMed ID: 38491717
[TBL] [Abstract][Full Text] [Related]
40. Metabolism and Disposition of Pacritinib (SB1518), an Orally Active Janus Kinase 2 Inhibitor in Preclinical Species and Humans.
Jayaraman R; Pasha MK; Williams A; Goh KC; Ethirajulu K
Drug Metab Lett; 2015; 9(1):28-47. PubMed ID: 25600203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
